These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9244658)

  • 21. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
    J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Side effects of drugs, individual hypertension therapy, and drug-taking behavior of patients].
    Teichmann G; Riethling AK
    Z Gesamte Inn Med; 1980 Oct; 35(19):suppl 103-5. PubMed ID: 7210749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed-drug combinations as first-line treatment for hypertension.
    Rosenthal T; Gavras I
    Prog Cardiovasc Dis; 2006; 48(6):416-25. PubMed ID: 16714161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil].
    Widimský J; Dzúrik R
    Vnitr Lek; 1998 Jun; 44(6):326-31. PubMed ID: 9820054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
    Sanoski CA
    Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
    Abe M; Okada K; Matsumoto K
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1285-303. PubMed ID: 19761411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [When blood pressure control is a problem. Refractory hypertension is rare].
    Offers E; Kolloch R
    MMW Fortschr Med; 2002 Nov; 144(46):42-4, 46. PubMed ID: 12534081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fixed-dosage combinations in the treatment of hypertension].
    Muiño Miguez A; López Glez-Cobos C; Villalba García MV; Segado Soriano A; Granda Martín MJ; Gil Gómez J
    An Med Interna; 1999 Feb; 16(2):92-6. PubMed ID: 10193003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment concepts in therapy refractory hypertension].
    Kolloch R; Offers E
    Fortschr Med; 1998 Jun; 116(18-19):22-6. PubMed ID: 9691533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The treatment of arterial hypertension: which drug for which patient?].
    Wafber B; Niederberger M; Nussberger J; Burnier M; Brunner HR
    Schweiz Rundsch Med Prax; 1992 Jan; 81(3):32-6. PubMed ID: 1732999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fixed antihypertensive drug combinations].
    Waeber B
    Ther Umsch; 1999 Jan; 56(1):33-6. PubMed ID: 10067132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevention of target organ damage with modern antihypertensive agents].
    Páll D; Katona E; Juhász M; Paragh G
    Orv Hetil; 2006 Aug; 147(32):1505-11. PubMed ID: 16981424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hypertension therapy and patient compliance].
    Rapi J
    Orv Hetil; 2002 Aug; 143(34):1979-83. PubMed ID: 12422651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Goal blood pressure values from the nephrologic viewpoint].
    Hörl WH
    Wien Med Wochenschr; 1999; 149(23-24):629-32. PubMed ID: 10721158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing the patient with hard-to-control hypertension.
    Oparil S; Calhoun DA
    Am Fam Physician; 1998 Mar; 57(5):1007-14, 1019-20. PubMed ID: 9518949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V
    Am J Cardiol; 2009 Jan; 103(2):273-8. PubMed ID: 19121451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.